Biogen Snags FDA Approval for Second Hemophilia Drug
The U.S. FDA said on Friday it approved Biogen Idec's long-lasting hemophilia A drug, Eloctate, adding another product to the company's emergent portfolio of non-malignant blood disorder drugs. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 10, 2014 Category: Pharmaceuticals Source Type: news

New Hemophilia Remedy Offers Potential for Fewer Injections
Title: New Hemophilia Remedy Offers Potential for Fewer InjectionsCategory: Health NewsCreated: 6/9/2014 12:35:00 PMLast Editorial Review: 6/10/2014 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - June 10, 2014 Category: Cardiology Source Type: news

FDA Clears First Long-Acting Hemophilia A Drug (Eloctate)FDA Clears First Long-Acting Hemophilia A Drug (Eloctate)
Eloctate requires fewer injections when used to prevent or reduce the frequency of bleeding than currently available products. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 10, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

New Long-Acting Hemophilia A Drug Approved (FREE)
By Kristin J. Kelley Edited by Susan Sadoughi, MD, and Jaye Elizabeth Hefner, MD The FDA has approved Eloctate, a new prophylactic treatment for children and adults … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 9, 2014 Category: Primary Care Source Type: news

Biogen Idec receives FDA approval for haemophilia A drug
Biogen Idec has received approval from the US Food and Drug Administration (FDA) for its Eloctate to control and prevent bleeding episodes, perioperative management, as well as routine prophylaxis in adults and children with haemophilia A. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 9, 2014 Category: Pharmaceuticals Source Type: news

Hemophilia A Drug Gets FDA Nod
(MedPage Today) -- SILVER SPRING, Md. -- A recombinant fusion drug combining the Factor VIII protein with a peptide to extend its lifetime in circulation has been approved for treating hemophilia A, the FDA said. (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - June 7, 2014 Category: American Health Source Type: news

U.S. FDA approves Biogen's hemophilia A drug Eloctate
WASHINGTON (Reuters) - The U.S. Food and Drug Administration said on Friday it approved Biogen Idec Inc's long-lasting hemophilia A drug, Eloctate, adding another product to the company's nascent portfolio of drugs for non-malignant blood disorders. (Source: Reuters: Health)
Source: Reuters: Health - June 6, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves the first antihemophilic factor, Fc fusion protein for patients with Hemophilia A
The U.S. Food and Drug Administration today approved Eloctate, Antihemophilic Factor (Recombinant), Fc fusion protein, for use in adults and children who have Hemophilia A. Eloctate is the first Hemophilia A treatment designed to require less frequent injections when used to prevent or reduce the frequency of bleeding. (Source: Food and Drug Administration)
Source: Food and Drug Administration - June 6, 2014 Category: American Health Source Type: news

Haemophilia and gene therapy
Attendees at the 19th Congress of the European Hematology Association will hear how patients are benefiting from advances in gene therapy, genome sequencing and new drug development. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 4, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: Haematology European Hematology Association Congress Featured Articles gene therapy Haemophilia Source Type: news

EMA adopts positive opinion on Octapharma’s haemophilia A drug Nuwiq
The European Medicines Agency (EMA) has given a positive opinion towards Octapharma's human cell line recombinant human FVIII, Nuwiq, recommending the granting of marketing authorisation for treatment and prophylaxis of bleeding in paediatric and adu… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 28, 2014 Category: Pharmaceuticals Source Type: news

Biogen to Donate 1 Billion Units of Hemophilia Treatment
Australia-based Biogen Idec announced their intent to donate one billion international units of clotting factor therapy for humanitarian aid programs in the developing world. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 13, 2014 Category: Pharmaceuticals Source Type: news

Bayer's Kogenate FS gets FDA approval for routine prophylaxis in Hemophilia A patients
Bayer HealthCare has received approval from the US Food and Drug Administration (FDA) for a new indication of its Kogenate FS antihemophilic factor VIII (recombinant), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 13, 2014 Category: Pharmaceuticals Source Type: news

Biogen, Sobi pledge hemophilia drug donation in developing world
(Reuters) - Biogen Idec Inc and partner Swedish Orphan Biovitrum AB on Monday said they will donate hemophilia drugs for use in developing nations in quantities large enough to treat tens of thousands of patients over the next decade. (Source: Reuters: Health)
Source: Reuters: Health - May 12, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Akorn Announces $440M VersaPharm Acquisition
Akorn aims to increase presence in the niche dermatology, tuberculosis and hemophilia markets (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 9, 2014 Category: Pharmaceuticals Source Type: news

Haemophilia society marks 25th anniversary of pivotal HIV debate
Howlin recalls his Bill which brought down Haughey government in 1989 (Source: The Irish Times - Health)
Source: The Irish Times - Health - April 29, 2014 Category: Consumer Health News Source Type: news

Kenya: The Pain of Living With Haemophilia
[Capital FM]Nairobi -"The hardest and most painful thing all through has been to tell my son that he cannot play football, yet when he asks why I cannot tell him that the actual reason is that his falling could prove to be fatal," narrates Lucy Kago a mother to Simon Musyoka who at seven years old, has protrusions on his elbow and ankles that at times are the cause of his excruciating pain. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - April 22, 2014 Category: African Health Source Type: news

Cameroon: Haemophilia, a Reality in Cameroon
[Cameroon Tribune]Ndzana Amboune, 11, a pupil of CEII is suffering from haemophilia; a congenital bleeding disorder. He arrived at the University Teaching Hospital (CHU) on April 16, 2014 on crutches. He was accompanied by two of his junior brothers and his mother, Mrs Ndzana who told CT that two of her sons are suffering from haemophilia and the last one has symptoms of haemophilia as well. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - April 21, 2014 Category: African Health Source Type: news

Hemophilia Treatments Have Come a Long Way
Patients have many choices when it comes to hemophilia medications. FDA’s regulation of the biologic products used as treatments ensures they are safe and effective. (Source: FDA Consumer Updates)
Source: FDA Consumer Updates - April 16, 2014 Category: Consumer Health News Source Type: news

Biogen Idec and Sobi announce positive top-line efficacy and safety results from phase-3 paediatric study of investigational therapy Eloctate(TM) (rFVIIIFc) for haemophilia A
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - April 10, 2014 Category: Pharmaceuticals Source Type: news

The Economist explains: Why gene therapy just got easier
SOME diseases, such as haemophilia and cystic fibrosis, are caused by broken genes. Doctors have long dreamed of treating them by adding working copies of these genes to cells in the relevant tissue (bone marrow and the epithelium of the lung respectively, in these two cases). This has proved hard. There have been a handful of qualified successes over the years, most recently involving attempts to restore vision to people with gene-related blindness. But this sort of gene therapy is likely to remain experimental and bespoke for a long time, as it is hard to get enough genes into enough cells in solid tissue to have a meani...
Source: Biotechnology - April 9, 2014 Category: Biotechnology Source Type: news

Biogen Gets FDA Approval for Milestone Hemophilia Therapy
The U.S. FDA has approved Biogen Idec's Alprolix, the first recombinant, DNA derived hemophilia B therapy with prolonged circulation in the body. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 8, 2014 Category: Pharmaceuticals Source Type: news

Alprolix, for Treatment of Haemophilia B
Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein] is an intravenous injection indicated for the control and prevention of bleeding episodes, as well as routine prophylaxis in haemophilia B-affected adults and children aged 12 years an… (Source: Drug Development Technology)
Source: Drug Development Technology - April 3, 2014 Category: Pharmaceuticals Source Type: news

Long-Acting Clotting Agent Approved for Form of Hemophilia
Title: Long-Acting Clotting Agent Approved for Form of HemophiliaCategory: Health NewsCreated: 3/31/2014 12:36:00 PMLast Editorial Review: 4/1/2014 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - April 1, 2014 Category: Cardiology Source Type: news

Biogen's haemophilia B drug Alprolix gets FDA approval
Biogen Idec has received approval from the US Food and Drug Administration (FDA) for its long-acting haemophilia B treatment Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein]. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 31, 2014 Category: Pharmaceuticals Source Type: news

New Hemophilia B Drug Wins FDA OK
(MedPage Today) -- SILVER SPRING, Md. -- A recombinant Factor IX protein drug (Alprolix) for hemophilia B that can be administered weekly or even less frequently has been approved by the FDA. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 28, 2014 Category: Primary Care Source Type: news

FDA approves first long-acting recombinant coagulation Factor IX concentrate for patients with Hemophilia B
The U.S. Food and Drug Administration today approved Alprolix, Coagulation Factor IX (Recombinant), Fc Fusion Protein, for use in adults and children who have Hemophilia B. Alprolix is the first Hemophilia B treatment designed to require less frequent injections when used to prevent or reduce the frequency of bleeding. (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 28, 2014 Category: American Health Source Type: news

Biogen's haemophilia B therapy Alprolix approved in Canada
US-based Biogen Idec has received approval from Health Canada for Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein], for the control and prevention of bleeding episodes and routine prophylaxis in adults and children aged 12 and older … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 24, 2014 Category: Pharmaceuticals Source Type: news

Biogen Idec wins Canadian approval for hemophilia drug Alprolix
(Reuters) - Biogen Idec Inc said on Friday it had won Canadian approval for its long-lasting hemophilia B drug Alprolix. (Source: Reuters: Health)
Source: Reuters: Health - March 21, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Top medicine articles for March 2014
A collection of some interesting medical articles published recently:1 in 10 U.S. Children Now Has ADHD, CDC Says http://buff.ly/IeqY1SLifestyle interventions effectively decrease the incidence of type 2 diabetes in high-risk patients http://buff.ly/1bSrw9jTime for another go at understanding vitamin D metabolism http://buff.ly/1hdob8fDo healthier foods cost more than less healthy options? Healthy eating costs an extra $1.50 per day - BMJ http://buff.ly/JEpi2t1% of women in a U.S. study who have become pregnant claim to have done so as virgins - BMJ/Reuters http://buff.ly/19zkHIZYou’re never too old to exercise: 98-y...
Source: Clinical Cases and Images - March 19, 2014 Category: Journals (General) Tags: Health News of the Day Source Type: news

Bayer To Invest $700M For Hemophilia A Drugs Production In Germany
Bayer announced it will invest more than 500 million euros or nearly $700 million to establish additional capacities for the manufacture of recombinant factor VIII (rFVIII) hemophilia A drugs currently under development. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - March 13, 2014 Category: Pharmaceuticals Source Type: news

Bayer to invest $700 million to produce haemophilia drugs in Germany
As part of the production expansion, Bayer will create about 500 new jobs at its sites in Leverkusen and Wuppertal by 2020. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 11, 2014 Category: Pharmaceuticals Source Type: news

11.03.14: Not intended for U.S. and UK Media
Bayer to invest more than 500 million Euros for the manufacturing of hemophilia A products currently in developmentExpansion of manufacturing capacities for innovative therapy optionsmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - March 11, 2014 Category: Pharmaceuticals Source Type: news

Bayer to invest more than 500 million Euros for the manufacturing of hemophilia A products currently in development (for specialized target groups only)
Expansion of manufacturing capacities for innovative therapy options (Source: Bayer Company News)
Source: Bayer Company News - March 11, 2014 Category: Pharmaceuticals Source Type: news

New Hemophilia Drugs Aim to Simplify TreatmentNew Hemophilia Drugs Aim to Simplify Treatment
Several new blood clotting agents in development will help hemophilia patients cut by half, or more, the number of regular intravenous infusions they need to prevent traumatic bleeding in their daily lives. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 10, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

New hemophilia drugs aim to simplify treatment
LOS ANGELES (Reuters) - For 33-year-old video editor and hemophilia patient Travis Roop, being able to get life-saving infusions of a blood clotting agent every two weeks, instead of rushing to treat a bleeding episode, meant he could jog for the first time. (Source: Reuters: Health)
Source: Reuters: Health - March 7, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

18.02.14: Not intended for U.S. and UK Media
Bayer's Long-Acting Recombinant Factor VIII Demonstrated Effective Prophylaxis with Less Frequent Infusions in Hemophilia A in Phase III TrialIn the PROTECT VIII study, BAY94-9027 met its primary efficacy and safety objectives for the treatment of patients with hemophilia A / Extending infusion intervals up to seven days resulted in protection from bleeds comparable to current prophylactic dose regimens / No patient developed inhibitors to factor VIII during the 36-week treatment periodmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - February 18, 2014 Category: Pharmaceuticals Source Type: news

Bayer's Long-Acting Recombinant Factor VIII Demonstrated Prophylaxis with Less Frequent Infusions in Hemophilia A in Phase III Trial
The PROTECT VIII study met its primary efficacy and safety objectives for the treatment of patients with hemophilia A BAY 94-9027 helped protect against bleeds when used prophylactically with infusion intervals up to seven days WHIPPANY, N.J., Feb. 1... BiopharmaceuticalsBayer HealthCare Pharmaceuticals, BAY 94-9027, factor VIII, hemophilia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 18, 2014 Category: Pharmaceuticals Source Type: news

Bayer’s Long-Acting Recombinant Factor VIII Demonstrated Effective Prophylaxis with Less Frequent Infusions in Hemophilia A in Phase III Trial (for specialized target groups only)
In the PROTECT VIII study, BAY94-9027 met its primary efficacy and safety objectives for the treatment of patients with hemophilia A / Extending infusion intervals up to seven days resulted in protection from bleeds comparable to current prophylactic dose regimens / No patient developed inhibitors to factor VIII during the 36-week treatment period (Source: Bayer Company News)
Source: Bayer Company News - February 18, 2014 Category: Pharmaceuticals Source Type: news

Rixubis (coagulation factor IX (recombinant)) for the Treatment of Haemophilia B
Rixubis [coagulation factor IX (recombinant)] is indicated for the control and prevention of bleeding episodes and perioperative management in the treatment of adult patients suffering from haemophilia B. (Source: Drug Development Technology)
Source: Drug Development Technology - February 3, 2014 Category: Pharmaceuticals Source Type: news

Baxter restructures licensing deal with Xenetic Biosciences
Baxter International has restructured its agreement with Xenetic Biosciences for the development of BAX 826, a recombinant Factor VIII treatment for haemophilia A, and also made a $10m investment in Xenetic. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 31, 2014 Category: Pharmaceuticals Source Type: news

Haemophilia should be 'no barrier' to life, writes specialist nurse
A haemophilia nurse consultant has contributed to a unique new book about the personal experiences of people affected by bleeding disorders.    (Source: Nursing Times Breaking News)
Source: Nursing Times Breaking News - January 24, 2014 Category: Nursing Source Type: news

Alnylam begins Phase I study of blood disorder drug
US-based Alnylam Pharmaceuticals has started a Phase I trial with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT), for the treatment of hemophilia and rare bleeding disorders (RBD). (Source: Drug Development Technology)
Source: Drug Development Technology - January 23, 2014 Category: Pharmaceuticals Source Type: news

A Conversation With Holbrook Kohrt: A Doctor’s Intimate View of Hemophilia
Holbrook Kohrt, a physician and researcher, has spent a lifetime as a patient. That experience informs every day of his work to find cures for cancer.     (Source: NYT Health)
Source: NYT Health - December 23, 2013 Category: Consumer Health News Authors: By CLAUDIA DREIFUS Tags: Doctors Kohrt, Holbrook Blood Hemophilia Source Type: news

Hemophilia: Current Management, Unmet NeedsHemophilia: Current Management, Unmet Needs
Dr. Neil C. Josephson reviews for Medscape current evidence-based treatment approaches in hemophilia and the unmet needs that must be addressed. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 23, 2013 Category: Consumer Health News Tags: Hematology-Oncology Article Source Type: news

FDA Approves Hemophilia Drug FEIBA for Bleeding Prophylaxis FDA Approves Hemophilia Drug FEIBA for Bleeding Prophylaxis
Previously marketed for treatment of bleeding in hemophilia, the anti-inhibitor coagulant complex is now available for prophylaxis. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 23, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia A&B patients with inhibitors
The US Food and Drug Administration (FDA) has approved Baxter's FEIBA [anti-inhibitor coagulant complex] for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A or B patients with inhibitors. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - December 23, 2013 Category: Pharmaceuticals Source Type: news

Hybrid clotting factor means fewer injections, better disease control for hemophilia patients
A Phase III clinical trial led by UC Davis researchers has confirmed that a new coagulation factor (rFIXFc) dramatically reduces the number of injections needed to maintain effective clotting for hemophilia B patients. The recombinant protein fuses clotting factor IX with an immunoglobulin (antibody) molecule, which prevents the body from rapidly metabolizing the hybrid protein. As a result, rFIXFc can be administered once a week, or even every two weeks, rather than every other (or every third) day. This extended half-life could have an enormous impact on hemophilia treatment. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 17, 2013 Category: Consumer Health News Tags: Blood / Hematology Source Type: news

Is there a protective link between hemophilia and long-term HIV infection?
People with the genetic blood clotting disorder hemophilia who have been infected with HIV for decades have an increased proportion of immune cells in their blood that specifically target HIV. This protective immune response helps chronically infected hemophilia patients survive, even during periods of HIV activity, according to a study published in BioResearch Open Access, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the BioResearch Open Access website. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 16, 2013 Category: Consumer Health News Tags: Blood / Hematology Source Type: news

Potential hemophilia treatment using new gene therapy
Researchers at the UNC School of Medicine and the Medical College of Wisconsin found that a new kind of gene therapy led to a dramatic decline in bleeding events in dogs with naturally occurring hemophilia A, a serious and costly bleeding condition that affects about 50,000 people in the United States and millions more around the world.Before the gene treatment, the animals experienced about five serious bleeding events a year. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 15, 2013 Category: Consumer Health News Tags: Blood / Hematology Source Type: news

National award honors CHOP scientist for career work in gene therapy for hemophilia
(Children's Hospital of Philadelphia) Katherine A. High, M.D., of The Children's Hospital of Philadelphia, was honored for her trailblazing scientific and clinical research in the bleeding disorder hemophilia when she received the 2013 E. Donnall Thomas Prize of the American Society of Hematology at its annual meeting on Dec. 9 in New Orleans. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 13, 2013 Category: Global & Universal Source Type: news